"This medication is not the panacea to tackle the maternal mental health crisis." -- Judite Blanc, PhD, of the University of Miami Miller School of Medicine, on the recent FDA approval of the zuranolone (Zurzuvae), the first pill for postpartum depression.
"I know that patients will have a difficult time knowing what the results mean, and many patients will draw the wrong conclusions." -- Suzanne Schindler, MD, PhD, of Washington University in St. Louis, discussing an Alzheimer's blood test from Quest that consumers can purchase from home without visiting a doctor first.
"I would be cautious about the study's conclusions that PPI [proton pump inhibitor] use is associated with risk of dementia." -- Andrew Chan, MD, of Harvard Medical School and Massachusetts General Hospital in Boston, commenting on a study suggesting cumulative use of prescribed PPIs may be linked with dementia in older adults.
"The only way we're going to fix some of the issues physicians face is to take back some of our ownership." -- Aaron Goodman, MD, of the University of California San Diego, discussing a petition calling for the American Board of Internal Medicine's maintenance of certification requirements to end.
"We don't really know exactly what advantage it has, but it is playing out in increased cases attributed to this variant." -- Shishi Luo, PhD, of Helix, on the latest COVID Omicron subvariant known as Eris.
"Most individuals with opioid use disorders are still not on recommended medications." -- Ashley Leech, PhD, MS, of Vanderbilt University School of Medicine in Nashville, discussing how out-of-pocket costs remain a barrier to buprenorphine use.
"This study should help assuage any concerns that generic inhalers may not function as well as brand-name versions." -- William Feldman, MD, DPhil, MPH, of Brigham and Women's Hospital in Boston, on finding that a generic fluticasone-salmeterol maintenance inhaler was clinically equivalent to name-brand one for COPD.
"What comes to mind are often young, white, unemployed men." -- Mark Olfson, MD, MPH, of Columbia University Irving Medical Center in New York City, discussing what some people think of when picturing who's at risk for drug overdose deaths.
"It is one thing to discuss the likely increase as a broad concept and another to give actual numbers, which then drive the point home more starkly." -- David Hackney, MD, of Case Western Reserve University in Cleveland, on the effect abortion bans may have on the incidence of neonatal cardiac defects.